{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:45:25Z","timestamp":1787168725995,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Previous trials showed the tolerability and efficacy of a palliative radiotherapy (RT) regimen (SHARON) based on the 4 fractions delivered in 2\u00a0days in different oncological settings. In order to identify possible predictors of symptomatic response, the purpose of this study is to perform a pooled analysis of previous trials. We analyzed the impact on symptomatic response of the following parameters: tumor site, histological type, performance status (ECOG), dominant symptom, and RT dose using the Chi-square test and Fisher\u2019s exact test. One-hundred-eighty patients were analyzed. Median RT dose was 20\u00a0Gy (range: 14\u201320\u00a0Gy). The overall response rate was 88.8% (95% CI 83.3\u201392.7%) while pre- and post-treatment mean VAS was 5.3 (\u00b1\u20097.7) and 2.2 (\u00b1\u20092.2), respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The overall response rate of pain, dyspnea, bleeding, dysphagia, and other symptoms was 86.2%, 90.9%, 100%, 87.5%, and 100%, respectively. Comparing the symptomatic effect based on the analyzed parameters no significant differences were recorded. However, patients with locally advanced disease showed a higher rate of symptomatic responses than metastatic ones (97.3% vs 83.0%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021). Finally, the complete pain response rate was more than double in patients with mild to moderate (VAS: 4\u20137) compared to those with severe (VAS\u2009&gt;\u20097) pain (36.0% vs 14.3%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028). This pooled analysis showed high efficacy of the SHARON regimen in the relief of several cancer-related symptoms. The markedly and significantly higher complete pain response rate, in patients with mild-moderate pain, suggests early referral to palliative RT for patients with cancer-related pain.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-25602-7","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T06:02:37Z","timestamp":1670220157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Short course palliative radiotherapy in advanced solid tumors: a pooled analysis (the SHARON project)"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-4510","authenticated-orcid":false,"given":"Costanza Maria","family":"Donati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giambattista","family":"Siepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Benini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milly","family":"Buwenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cammelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Caravatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tigeneh","family":"Wondemagegnhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F. M. Kamal","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biniyam Tefera","family":"Deressa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa A.","family":"Sumon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lodi Rizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bazzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio G.","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"issue":"29","key":"25602_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/0360-3016(94)90389-1","volume":"30","author":"WJ Spanos Jr","year":"1994","unstructured":"Spanos, W. J. Jr. et al. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int. J. Radiat. Oncol. Biol. Phys. 30(29), 961\u2013967 (1994).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"25602_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/0360-3016(89)90120-X","volume":"17","author":"W Spanos Jr","year":"1989","unstructured":"Spanos, W. Jr. et al. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int. J. Radiat. Oncol. Biol. Phys. 17, 659\u2013661 (1989).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"25602_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.radonc.2005.10.008","volume":"77","author":"J Corry","year":"2005","unstructured":"Corry, J. et al. The \u201cQUAD SHOT\u201d: a Phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother. Oncol. 77, 137\u2013142 (2005).","journal-title":"Radiother. Oncol."},{"key":"25602_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.oraloncology.2015.07.011","volume":"51","author":"BH Lok","year":"2015","unstructured":"Lok, B. H. et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 51, 957\u2013962 (2015).","journal-title":"Oral Oncol."},{"key":"25602_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13014-020-01548-w","volume":"15","author":"R Toya","year":"2020","unstructured":"Toya, R. et al. Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 \u201cQUAD shot\u201d regimen for incurable head and neck cancer. Radiat. Oncol. 15, 123 (2020).","journal-title":"Radiat. Oncol."},{"key":"25602_CR6","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/j.ijrobp.2011.10.081","volume":"83","author":"L Caravatta","year":"2012","unstructured":"Caravatta, L. et al. Short-course accelerated radiotherapy in palliative treatment of advanced pelvic malignancies: a Phase I study. Int. J. Radiat. Oncol. Biol. Phys. 83, e627\u2013e631 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"25602_CR7","first-page":"2409","volume":"38","author":"E Farina","year":"2018","unstructured":"Farina, E. et al. Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer. Anticancer Res. 38, 2409\u20132414 (2018).","journal-title":"Anticancer Res."},{"key":"25602_CR8","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.21873\/anticanres.13585","volume":"39","author":"E Farina","year":"2019","unstructured":"Farina, E. et al. Palliative short-course radiotherapy in advanced pelvic cancer: a phase II study (SHARON Project). Anticancer Res. 39, 4237\u20134242 (2019).","journal-title":"Anticancer Res."},{"key":"25602_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10585-018-9931-9","volume":"35","author":"J Capuccini","year":"2018","unstructured":"Capuccini, J. et al. Short-course regimen of palliative radiotherapy in complicated bone metastases: a Phase I-II study (SHARON Project). Clin. Exp. Metastasis. 35, 605\u2013611 (2018).","journal-title":"Clin. Exp. Metastasis."},{"key":"25602_CR10","unstructured":"Morgan-Fletcher, S. L. Prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50), ICRU Report 62. ICRU, pp ix + 52, 1999 (ICRU Bethesda, MD). https:\/\/www.icru.org\/report\/prescribing-recording-and-reporting-photon-beam-therapy-report-62\/ (1999)."},{"key":"25602_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1177\/030089161209800407","volume":"98","author":"F Deodato","year":"2012","unstructured":"Deodato, F. et al. Daily on-line set-up correction in 3D-conformal radiotherapy: is it feasible?. Tumori 98, 441\u2013444 (2012).","journal-title":"Tumori"},{"issue":"5","key":"25602_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00002820-198810000-00006","volume":"11","author":"HJ Sutherland","year":"1988","unstructured":"Sutherland, H. J., Walker, P. & Til, J. E. The development of a method for determining oncology patients\u2019 emotional distress using linear analogue scales. Cancer Nurs. 11(5), 303\u2013308 (1988).","journal-title":"Cancer Nurs."},{"key":"25602_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0360-3016(01)01495-X","volume":"50","author":"OM Salazar","year":"2001","unstructured":"Salazar, O. M. et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int. J. Radiat. Oncol. Biol. Phys. 50, 765\u2013775 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"25602_CR14","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","volume":"82","author":"E Chow","year":"2012","unstructured":"Chow, E. et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int. J. Radiat. Oncol. Biol. Phys. 82, 1730\u20131737 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"25602_CR15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox, J. D., Stetz, J. & Pajak, T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J Radiat. Oncol. Biol. Phys. 31, 1341\u20131346 (1995).","journal-title":"Int. J Radiat. Oncol. Biol. Phys."},{"key":"25602_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijrobp.2018.04.072","volume":"101","author":"T Saito","year":"2018","unstructured":"Saito, T. et al. Predictors of pain palliation after radiation therapy for painful tumors: a prospective observational study. Int. J. Radiat. Oncol. Biol. Phys. 101, 1061\u20131068 (2018).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"25602_CR17","first-page":"1097","volume":"10","author":"J Shin","year":"2022","unstructured":"Shin, J. et al. Distinct worst pain profiles in oncology outpatients undergoing chemotherapy. Cancer Nurs. 10, 1097 (2022).","journal-title":"Cancer Nurs."},{"key":"25602_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00066-021-01760-x","volume":"197","author":"T Saito","year":"2021","unstructured":"Saito, T. et al. Influence of pain duration on pain outcomes following palliative radiotherapy for painful tumors: the sooner the irradiation, the better?. Strahlenther. Onkol. 197, 916\u2013925 (2021).","journal-title":"Strahlenther. Onkol."},{"key":"25602_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/acm2.12427","volume":"19","author":"S Cilla","year":"2018","unstructured":"Cilla, S. et al. Partially ablative radiotherapy (PAR) for large mass tumors using simultaneous integrated boost: a dose-escalation feasibility study. J. Appl. Clin. Med. Phys. 19, 35\u201343 (2018).","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"25602_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.clon.2021.08.011","volume":"33","author":"H Fukunaga","year":"2021","unstructured":"Fukunaga, H., Butterworth, K. T., McMahon, S. J. & Prise, K. M. A brief overview of the preclinical and clinical radiobiology of microbeam radiotherapy. Clin. Oncol. (R Coll. Radiol.) 33, 705\u2013712 (2021).","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"key":"25602_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2019.10.004","volume":"106","author":"BT Deressa","year":"2020","unstructured":"Deressa, B. T. et al. Short-course 2-dimensional radiation therapy in the palliative treatment of esophageal cancer in a developing country: a Phase II study (Sharon Project). Int. J. Radiat. Oncol. Biol. Phys. 106, 67\u201372 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25602-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T06:20:33Z","timestamp":1670221233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25602-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25602-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20978"}}